Alzheimer’s Patients Could Die From Risperdal: Study

Law360, New York (January 9, 2009, 12:00 AM EST) -- A new study has found that Alzheimer’s disease patients who take anti-psychotic drugs such as Johnson & Johnson's Risperdal may face a doubled risk of death, further bolstering concerns over a possible correlation between such medications and a higher death rate in individuals with dementia.

The study, published Friday in the medical journal Lancet, found an increased long-term risk of mortality in patients with Alzheimer's who are prescribed anti-psychotic medication.

“Estimates of mortality for the whole study period showed a significantly increased risk of mortality for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.